Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-07-03T23:42:48.073Z Has data issue: false hasContentIssue false

Schizophrenia and substance use disorders: Effects of zyprasidone treatment

Published online by Cambridge University Press:  16 April 2020

J. Canete
Affiliation:
Department of Psychiatry, Consorci Sanitari del Maresme, Hospital de Mataró, Mataró, Barcelona, Spain
I. Alonso
Affiliation:
Department of Psychiatry, Consorci Sanitari del Maresme, Hospital de Mataró, Mataró, Barcelona, Spain
F. Baron
Affiliation:
Department of Psychiatry, Consorci Sanitari del Maresme, Hospital de Mataró, Mataró, Barcelona, Spain
G. Gonzalez
Affiliation:
Department of Psychiatry, Consorci Sanitari del Maresme, Hospital de Mataró, Mataró, Barcelona, Spain

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Background and aims:

The risk of abuse/dependence of alcohol or drugs in schizofrenia have been estimed about 4 times the prevalence in general population. This fact difficults the treatment results and efficcacy: more relapses, more treatments withdrawal and poorer prognosis. The aims of our study is to evaluate the effect of Zyprasidone, an atypical antipsychotic with 5HT propierties, in patients with schizofrenia and comorbid substance use disorder in a single, open, prospective-naturalistic design.

Method:

36 outpatients were selected with Schizofrenic disorder diagnosis (DSMIV) and abuse/dependence of at least 1 substance in which Zyprasidone was recommended (inneficacy, intolerance of prior treatments,..). They were evaluated clinically and data about actual consum and craving were collected at inicial visit and follow-up monthly (3 to 6 months). Results were analized with SPSS pack.

Results:

The mean follow-up period was 3 month. 28 patients finished the evaluation showing a decrease in clinical measures (PANSS, ICG) with good tolerance (only 4 drop-outs associated to indesirable effects). The most frequent drug use disorder was tobacco followed by alcohol and cannabis.The results on number and frequency of drug use shows a slow tendency to reduce at the end of the evaluation as well the craving measures but no significant differences were found.

Conclusions:

Our exploratory study with Zyprasidone, althougt metodological limitations, suggests that clinical schizofrenic symptoms can improve but also drug pattern use. Naturalistic studies of schizofrenia with comorbid substance use disorder can be useful to show the efficacy of antipsychotics in real clinical practice

Type
Poster Session 1: Antipsychotic Medications
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.